Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Troriluzole + Ipilimumab + Nivolumab in Melanoma Brain Metastases
NCT04899921Phase 2Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jun 2021
- Primary completion
- May 2023
- Modality
- Allosteric Modulators, Orthosteric Ligands, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of troriluzole in melanoma (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Median Global Progression-Free Survival at 5 years. Started Jun 2021; status: terminated.
02
Drugs
troriluzole
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04899921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04899921.